Business
Cannara Biotech Delivers Record Fiscal 2025 Revenue and Profitability, Achieves First Year of Positive Retained Earnings
Record Fiscal 2025 Financial Performance: Record net revenues of $107.3 million, adjusted EBITD...
About this update from Cannara Biotech, Inc.
[{"type":"text","content":"Cannara Biotech Delivers Record Fiscal 2025 Revenue and Profitability, Achieves First Year of Positive Retained Earnings\n\n\n\n\n\n Record Fiscal 2025 Financial Performance:\n \n Record net revenues of $107.3 million, adjusted EBITDA of $28.1 million\n \n 1\n \n , net income of $13.1 million, operating cash flow of $20 million and free cash flow of $13.7 million\n \n 1\n \n for Fiscal 2025.\n \n\n\n Stronger Balance Sheet and Earnings Quality:\n \n First year of positive retained earnings as at August 31, 2025, supported by continued free cash flow generation and lower leverage.\n \n\n\n Continued Market Share Expansion:\n \n National market share rose to 3.81% in Fiscal 2025, up 32% year over year, and climbed further to 4.1% in October 2025\n \n 2\n \n .\n \n\n Annual General Meeting of shareholders scheduled for January 29, 2026, at 11:00 a.m. EST.\n \n\n\n\n All financial results are reported in Canadian dollars, unless otherwise stated.\n \n\n\n MONTREAL, Nov. 24, 2025 (GLOBE NEWSWIRE) --\n \n\n Cannara Biotech Inc.\n \n\n (“\n \n Cannara\n \n ”, “the\n \n Company\n \n ”, “\n \n us\n \n ” or “\n \n we\n \n ”) (\n \n\n TSXV: LOVE\n \n\n ) (\n \n\n OTCQB: LOVFF\n \n\n ) (\n \n\n FRA: 8CB0\n \n\n ), a vertically integrated producer of premium-grade cannabis products at affordable prices with two mega facilities based in Québec spanning over 1,650,000 sq. ft., today announced its financial and operating results for the three and twelve-month periods ended August 31, 2025.The full set of annual audited consolidated consolidated financial statements for year ended August 31, 2025 and the accompanying Management’s Discussion and Analysis can be accessed by visiting the Company’s website at\n \n\n investors.cannara.ca\n \n\n , or by accessing the Company’s SEDAR+ profile at\n \n\n www.sedarplus.ca\n \n\n . The Company’s latest investor presentation is available at\n \n\n www.cannara.ca/investors/investor-deck/\n \n\n .\n \n\n\n Management Commentary:\n \n\n\n “Fiscal 2025 represents the strongest annual performance in Cannara Biotech’s history and reflects our ability to execute on the significant growth opportunity in front of us,” stated Zohar Krivorot, President and Chief Executive Officer of Cannara. “During the...